Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020
28 févr. 2020 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook
08 janv. 2020 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia
26 nov. 2019 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market
25 nov. 2019 14h11 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market
21 nov. 2019 11h30 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002
21 nov. 2019 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Third Quarter 2019 Financial Results
15 nov. 2019 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019
08 nov. 2019 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors
15 oct. 2019 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent
25 sept. 2019 08h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...